Bayer says FDA accepts Lynkuet sNDA, grants priority review
The U.S. FDA accepted Bayer’s supplemental New Drug Application for Lynkuet and granted Priority Review for a new indication in women receiving endocrine therapy for breast cancer. The filing is based on Phase III OASIS-4 data.